Cost of Basaglar (Insulin Glargine) in the United States

Pricing Details for Basaglar (Insulin Glargine Biosimilar/Follow-on Product)

The cost of Basaglar (insulin glargine) in the United States is approximately $95-$118 per 1,000 units for vials and $74-$190 per 1,000 units for prefilled pens, according to the American Diabetes Association guidelines 1, 2
The median Average Wholesale Price (AWP) for Basaglar U-100 vials is approximately $118 per 1,000 units, as recommended by the American Diabetes Association 2
The median National Average Drug Acquisition Cost (NADAC) for Basaglar U-100 vials is approximately $95 per 1,000 units, based on data from the American Diabetes Association 2
For prefilled pens, the median AWP ranges from $74 to $323, with an average of about $190 per 1,000 units, according to the American Diabetes Association guidelines 1

Insulin detemir (Levemir) costs $370 per 1,000 units, which is significantly more expensive than Basaglar, as reported by the American Diabetes Association 1
Insulin degludec (Tresiba) costs $85-$142 per 1,000 units for generic versions, which is comparable to Basaglar, according to the American Diabetes Association guidelines 1
Original insulin glargine (Lantus) costs $136 per 1,000 units for generic versions, which is more expensive than Basaglar, as recommended by the American Diabetes Association 1
Concentrated insulin glargine U-300 (Toujeo) costs $363 per 1,000 units, which is significantly more expensive than Basaglar, according to the American Diabetes Association guidelines 1

Dosage form affects cost, with prefilled pens typically costing more than vials, as reported by the American Diabetes Association 1
Insurance coverage affects out-of-pocket costs, which vary significantly based on insurance plans, according to the American Diabetes Association guidelines 3, 4
Pharmacy selection affects cost, with some pharmacies offering human insulins at significantly lower prices (approximately $25/vial), as recommended by the American Diabetes Association 5, 1

The cost of insulin therapy should be considered alongside other diabetes management costs, including blood glucose monitoring supplies and insulin administration devices, according to the American Diabetes Association guidelines 5, 1